The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro-Oncology
Abstract
Oligodendroglial tumors have attracted great interest in both basic and clinical neuro-oncology over the past decade. This interest is mainly due to the clinical observation that anaplastic oligodendrogliomas and anaplastic oligoastrocytomas, in contrast to the vast majority of anaplastic astrocytomas and glioblastomas, frequently respond favorably to chemotherapy. In addition, oligodendroglial tumors are associated with longer survival times than the diffuse astrocytic gliomas. These differences in response to therapy and in prognosis have been associated with distinct genetic aberrations, in particular the frequent loss of alleles on chromosome arms 1p and 19q in oligodendroglial tumors. In addition, other genetic changes have been reported as indicators of poor response to therapy and short survival, including homozygous deletion of the CDKN2A gene at 9p21, mutation of the PTEN gene at 10q23, and amplification of the EGFR gene at 7p12. In this review we summarize the current state of the art concerning the molecular genetics of oligodendroglial tumors. A particular focus is placed on the role of molecular genetic findings in the diagnostic and prognostic assessment of these neoplasms. As a result of the recent advances in the field, we propose that clinical decisions in the management of patients with oligodendroglial tumors should be based on the combined assessment of clinical and neuroimaging features, histological classification and grading, as well as molecular genetic characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
CpG island methylator phenotype in colorectal cancer
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J.-P. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8681 · Cited by 2,523
Prediction of central nervous system embryonal tumour outcome based on gene expression
Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin, M. E., Kim, J. Y. H., Goumnerova, L. C., Black, P. M., Lau, C., et al. (2002) · Nature · doi:10.1038/415436a · Cited by 2,371
Self-citationInactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Self-citationEsteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
Esteller, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205600 · Cited by 1,233
The INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 996
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Smith, J. S., Perry, A., Borell, T. J., Lee, H. K., O’Fallon, J., Hosek, S. M., Kimmel, D., Yates, A., Burger, P. C., Scheithauer, B. W., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.636 · Cited by 804
REIFENBERGER, J., Reifenberger, G., Liu, L., James, C. D., Wechsler, W., & Collins, V. P. (1994) · PubMed Central · Cited by 601
Self-citationp73: Friend or foe in tumorigenesis
Melino, G., De Laurenzi, V., & Vousden, K. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc861 · Cited by 560
Ino, Y., Betensky, R. A., Ƶlatescu, M. C., Sasaki, H., Macdonald, D. R., Stemmer-Rachamimov, A. O., Ramsay, D. A., Cairncross, J. G., & Louis, D. N. (2001) · PubMed · Cited by 432
Self-citationCDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., & Louis, D. N. (1996) · PubMed · Cited by 404
Self-citation(1992) · PubMed · Cited by 383
Smith, J. S., Alderete, B., Minn, Y., Borell, T. J., Perry, A., Mohapatra, G., Hosek, S. M., Kimmel, D., O'Fallon, J., Yates, A., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202759 · Cited by 374
Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia.
Esteller, M., Corn, P. G., Ureña, J. M., Gabrielson, E. W., Baylin, S. B., & Herman, J. G. (1998) · PubMed · Cited by 356
Rickman, D. S., Bobek, M. P., Misek, D. E., Kuick, R. D., Blaivas, M., Kurnit, D. M., Taylor, J. M. G., & Hanash, S. (2001) · PubMed · Cited by 352
KRAUS, J. A., KOOPMANN, J., KASKEL, P., MAINTZ, D., BRANDNER, S., SCHRAMM, J., LOUIS, D. N., WIESTLER, O. D., & VON DEIMLING, A. (1995) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199501000-00011 · Cited by 349
Self-citationSuccessful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 344
PTEN mutations in gliomas and glioneuronal tumors
Duerr, E.-M., Rollbrocker, B., Hayashi, Y., Peters, N., Meyer-Puttlitz, B., Louis, D. N., Schramm, J., Wiestler, O. D., Parsons, R., Eng, C., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201756 · Cited by 344
Self-citationΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors
Zaika, A. I., Slade, N., Erster, S. H., Sansome, C., Joseph, T. W., Pearl, M., Chalas, E., & Moll, U. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020179 · Cited by 318
Ichimura, K., Schmidt, E., Goike, H., & Collins, V. P. (1996) · PubMed · Cited by 307
Louis, D. N., Holland, E. C., & Cairncross, J. G. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61750-6 · Cited by 298
Self-citationRiemenschneider, M. J., Büschges, R., Wolter, M., REIFENBERGER, J., Boström, J. P., Kraus, J. A., Schlegel, U. S., & Reifenberger, G. (1999) · PubMed · Cited by 297
Self-citationCpG island methylator phenotypes in aging and cancer
Toyota, M., & Issa, J.-P. J. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0135 · Cited by 288
Towards a novel classification of human malignancies based on gene expression patterns
Alizadeh, A. A., Ross, D. T., Perou, C. M., & van de Rijn, M. (2001) · The Journal of Pathology · doi:10.1002/path.889 · Cited by 280
Mitotic recombination of chromosome 17 in astrocytomas.
James, C. D., Carlbom, E., Nordenskjold, M., Collins, V. P., & Cavenee, W. K. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2858 · Cited by 279
Bigner, S. H., Matthews, M. R., Rasheed, B. K. A., Wiltshire, R. N., Friedman, H. S., Friedman, A. H., Stenzel, T. T., Dawes, D. M., McLendon, R. E., & Bigner, D. D. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65134-6 · Cited by 268
Molecular Genetic Evidence for Subtypes of Oligoastrocytomas
MAINTZ, D., FIEDLER, K., KOOPMANN, J., ROLLBROCKER, B., NECHEV, S., LENARTZ, D., STANGL, A. P., LOUIS, D. N., SCHRAMM, J., WIESTLER, O. D., et al. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00003 · Cited by 247
Self-citationTumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.
Ƶlatescu, M. C., TehraniYazdi, A., Sasaki, H., Megyesi, J. F., Betensky, R. A., Louis, D. N., & Cairncross, J. G. (2001) · PubMed · Cited by 235
Self-citationOligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading
Giannini, C., Scheithauer, B. W., Weaver, A. L., Burger, P. C., Kros, J. M., Mork, S., Graeber, M. B., Bauserman, S., Buckner, J. C., Burton, J., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.3.248 · Cited by 219 · cited 1×
“The absence of reliable immunohistochemical markers for oligodendrogliomas and the fact that malignant gliomas may show ambiguous histological features of both astrocytic and oligodendroglial lineage underlie the considerable inter-observer variability in the classification of these tumors, even among experienced neur…”
BackgroundAllelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
Bauman, G. S., Ino, Y., Ueki, K., Zlatescu, M. C., Fisher, B. J., Macdonald, D. R., Stitt, L., Louis, D. N., & Cairncross, J. G. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00703-3 · Cited by 218
Self-citationImpact of Genotype and Morphology on the Prognosis of Glioblastoma
Schmidt, M. C., Antweiler, S., Urban, N., Mueller, W., Kuklik, A., Meyer-Puttlitz, B., Wiestler, O. D., Louis, D. N., Fimmers, R., & von Deimling, A. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.4.321 · Cited by 211
Self-citationvon Deimling, A., Louis, D. N., von Ammon, K., Petersen, I., Wiestler, O., & Seizinger, B. R. (1992) · PubMed · Cited by 210
Self-citationMueller, W., Hartmann, C., Hoffmann, A., Lanksch, W., Kiwit, J., Tonn, J., Veelken, J., Schramm, J., Weller, M., Wiestler, O. D., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64183-1 · Cited by 178
Self-citationOligodendrocyte lineage genes ( OLIG ) as molecular markers for human glial brain tumors
Lu, Q. R., Park, J. K., Noll, E., Chan, J. A., Alberta, J., Yuk, D., Alzamora, M. G., Louis, D. N., Stiles, C. D., Rowitch, D. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181340798 · Cited by 176
Self-citationInfluence of Unrecognized Molecular Heterogeneity on Randomized Clinical Trials
Betensky, R. A., Louis, D. N., & Gregory Cairncross, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.140 · Cited by 167
Self-citationNigro, J. M., Takahashi, M. A., Ginzinger, D. G., Law, M., Passe, S., Jenkins, R. B., & Aldape, K. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64076-x · Cited by 167
Transactivation-deficient DeltaTA-p73 acts as an oncogene.
Stiewe, T., Zimmermann, S., Frilling, A., Esche, H., & Pützer, B. M. (2002) · PubMed · Cited by 163
Josefa Bello, M., Leone, P. E., Vaquero, J., De Campos, J. M., Elena Kusak, M., Sarasa, J. L., Pestaña, A., & Rey, J. A. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640311 · Cited by 160
Sasaki, H., Zlatescu, M. C., Betensky, R. A., Ino, Y., Cairncross, J. G., & Louis, D. N. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61702-6 · Cited by 159
Self-citationWeber, R. G., Sabel, M., REIFENBERGER, J., Sommer, C., Oberstraß, J., Reifenberger, G., Kiessling, M., & Cremer, T. J. (1996) · PubMed · Cited by 158
Self-citationIno, Y., Ƶlatescu, M. C., Sasaki, H., Macdonald, D. R., Stemmer-Rachamimov, A. O., Jhung, S., Ramsay, D. A., von Deimling, A., Louis, D. N., & Cairncross, J. G. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.92.6.0983 · Cited by 151
Self-citationSilber, J. R., Bobola, M. S., Ghatan, S., Blank, A., Kolstoe, D. D., & Berger, M. S. (1998) · PubMed · Cited by 144
OLIG2 as a specific marker of oligodendroglial tumour cells
Marie, Y., Sanson, M., Mokhtari, K., Leuraud, P., Kujas, M., Delattre, J., Poirier, J. C., Zalc, B., & Hoang‐Xuan, K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05499-x · Cited by 144
Sasaki, H., Ƶlatescu, M. C., Betensky, R. A., Johnk, L., Cutone, A. N., Cairncross, J. G., & Louis, D. N. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.1.58 · Cited by 142
Self-citationKim, L., Hochberg, F. H., Thornton, A. F., et al. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.85.4.0602 · Cited by 139
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma
Macdonald, D., Gaspar, L. E., & Cairncross, J. G. (1990) · Annals of Neurology · doi:10.1002/ana.410270519 · Cited by 138
Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas
Watanabe, T., Nakamura, M., Kros, J. M., Burkhard, C., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2001) · Acta Neuropathologica · doi:10.1007/s004010100464 · Cited by 134
Microarrays as Cancer Keys: An Array of Possibilities
Mohr, S., Leikauf, G. D., Keith, G., & Rihn, B. H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.073 · Cited by 134
Burger, P. C. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00440.x · Cited by 127
Smith, J. S., Wang, X.-Y., Qian, J., Hosek, S. M., Scheithauer, B. W., Jenkins, R. B., & James, C. D. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.6.495 · Cited by 125
Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression
Hoang‐Xuan, K., He, J., Huguet, S., et al. (2001) · Neurology · doi:10.1212/wnl.57.7.1278 · Cited by 124
Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components
Actor, B., Cobbers, J. M. J. L., Büschges, R., Wolter, M., Knobbe-Thomsen, C. B., Reifenberger, G., & Weber, R. G. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10087 · Cited by 124
Self-citationConcurrent Hypermethylation of Multiple Genes Is Associated with Grade of Oligodendroglial Tumors
Dong, S.-M., Pang, J. C., Poon, W. S., Hu, J., To, K., Chang, A. R., & Ng, H. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.808 · Cited by 120
Small Cell Architecture—A Histological Equivalent of EGFR Amplification in Glioblastoma Multiforme?
Burger, P. C., Pearl, D. K., Aldape, K., Yates, A. J., Scheithauer, B. W., Passe, S. M., Jenkins, R. B., & James, C. D. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.11.1099 · Cited by 117
Epidermal growth factor receptor expression in oligodendroglial tumors.
REIFENBERGER, J., Reifenberger, G., Ichimura, K., Schmidt, E., Wechsler, W., & Collins, V. P. (1996) · Europe PMC (PubMed Central) · Cited by 110
Self-citationConcurrent Inactivation of RB1 and TP53 Pathways in Anaplastic Oligodendrogliomas
Watanabe, T., Yokoo, H., Yokoo, M., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.12.1181 · Cited by 104
Wolter, M., REIFENBERGER, J., Blaschke, B., Ichimura, K., Schmidt, E., Collins, V. P., & Reifenberger, G. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.12.1170 · Cited by 98
Self-citationFuller, G. N., Hess, K. R., Rhee, C. H., Yung, W. K. A., Sawaya, R. A., Bruner, J. M., & Zhang, W. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00427.x · Cited by 96
Blümcke, I., Becker, A. J., Normann, S., Hans, V., Riederer, B. M., Krajewski, S., Wiestler, O. D., & Reifenberger, G. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.10.984 · Cited by 95
Self-citationPohl, U., Smith, J. S., Tachibana, I., Ueki, K., Lee, H. K., Ramaswamy, S., Wu, Q., Mohrenweiser, H. W., Jenkins, R. B., & Louis, D. N. (2000) · Genomics · doi:10.1006/geno.1999.6087 · Cited by 91
Self-citationWatanabe, T., Nakamura, M., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2001) · Acta Neuropathologica · doi:10.1007/s004010000343 · Cited by 88
Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q.
von Deimling, A., Bender, B., Jahnke, R., Waha, A., Kraus, J., Albrecht, S., Wellenreuther, R., Faßbender, F., Nagel, J., & Menon, A. G. (1994) · PubMed · Cited by 88
Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p
Mukasa, A., Ueki, K., Matsumoto, S., Tsutsumi, S., Nishikawa, R., Fujimaki, T., Asai, A., Kirino, T., & Aburatani, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205495 · Cited by 84
Smith, J. S., Tachibana, I., Lee, H. K., Qian, J., Pohl, U., Mohrenweiser, H. W., Borell, T. J., Hosek, S. M., Soderberg, C. L., von Deimling, A., et al. (2000) · Genes Chromosomes and Cancer · Cited by 84
Self-citationTumour suppressor activity of human imprinted gene PEG3 in a glioma cell line
Kohda, T., Asai, A., Kuroiwa, Y., Kobayashi, S., Aisaka, K., Nagashima, G., Yoshida, M. C., Kondo, Y., Kagiyama, N., Kirino, T., et al. (2001) · Genes to Cells · doi:10.1046/j.1365-2443.2001.00412.x · Cited by 82
Watson, M. A., Perry, A., Budhraja, V., Budhjara, V., Hicks, C., Shannon, W. D., & Rich, K. M. (2001) · PubMed · Cited by 80
Peg3/Pw1 Is a Mediator between p53 and Bax in DNA Damage-induced Neuronal Death
Johnson, M. D., Wu, X., Aithmitti, N., & Morrison, R. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201907200 · Cited by 74
Peg3/Pw1 Is Involved in p53-mediated Cell Death Pathway in Brain Ischemia/Hypoxia
Yamaguchi, A., Taniguchi, M., Hori, O., Ogawa, S., Tojo, N., Matsuoka, N., Miyake, S., Kasai, K., Sugimoto, H., Tamatani, M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107435200 · Cited by 74
Mai, M., Huang, H., Reed, C., Qian, C., Smith, J. S., Alderete, B. E., Jenkins, R. B., Smith, D. I., & Liu, W. (1998) · Genomics · doi:10.1006/geno.1998.5387 · Cited by 69
Hartmann, C. J., Johnk, L., Kitange, G. J., Wu, Y., Ashworth, L. K., Jenkins, R. B., & Louis, D. N. (2002) · PubMed · Cited by 68
Self-citationSubtyping of oligo-astrocytic tumours by comparative genomic hybridization
Jeuken, J. W. M., Sprenger, S. H. E., Boerman, R. H., von Deimling, A., Teepen, H. L. J. M., van Overbeeke, J. J., & Wesseling, P. (2001) · The Journal of Pathology · doi:10.1002/path.837 · Cited by 62
Maier, D., Comparone, D., Taylor, E., Zhang, Z., Gratzl, O., Meir, E. G. V., Scott, R. J., & Merlo, A. U. (1997) · Oncogene · doi:10.1038/sj.onc.1201209 · Cited by 56
Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas
Zhu, J., Santarius, T., Wu, X., Tsong, J., Guha, A. R., Wu, J. K., Hudson, T. J., & Black, P. M. (1998) · Genes Chromosomes and Cancer · Cited by 54
Pohl, U., Cairncross, J. G., & Louis, D. N. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00545.x · Cited by 47
Self-citationCurrent Treatment of Oligodendrogliomas
Perry, J., Louis, D. N., & Cairncross, J. G. (1999) · Archives of Neurology · doi:10.1001/archneur.56.4.434 · Cited by 47
Self-citationMethylation of the p73 gene in gliomas
Watanabe, T., Huang, H., Nakamura, M., Wischhusen, J., Weller, M., Kleihues, P., & Ohgaki, H. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0549-1 · Cited by 46
Mutation analysis of the p73 gene in nonastrocytic brain tumours
Alonso, M. E., Bello, M. J., González‐Gómez, P., Lomas, J., Arjona, D., de Campos, J. M., Kusak, M. E., Sarasa, J. L., Isla, A., & REY, J. A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1855 · Cited by 40
Suzuki, S. O., Kitai, R., Llena, J., Lee, S. C., Goldman, J. E., & Shafit‐Zagardo, B. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.403 · Cited by 39
PTEN Mutation Analysis in Two Genetic Subtypes of High-Grade Oligodendroglial Tumors
Jeuken, J. W. M., Nelen, M. R., Vermeer, H., van Staveren, W. C. G., Kremer, H., van Overbeeke, J. J., & Boerman, R. H. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00210-1 · Cited by 29
OLIG‐1 and 2 gene expression and oligodendroglial tumours
Hoang‐Xuan, K., Aguirre‐Cruz, L., Mokhtari, K., Marie, Y., & Sanson, M. (2002) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2002.00395.x · Cited by 29
Bauman, G. S., & Cairncross, J. G. (2001) · Seminars in Radiation Oncology · doi:10.1053/srao.2001.21429 · Cited by 24
New perspectives for the diagnosis and treatment of oligodendroglioma
van den Bent, M. J. (2001) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.1.3.348 · Cited by 20
Novel PLA2G4C Polymorphism as a Molecular Diagnostic Assay for 19q Loss in Human Gliomas
Hartmann, C. J., Johnk, L., Sasaki, H., Jenkins, R. B., & Louis, D. N. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00432.x · Cited by 4
Self-citation
Cited by
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
“Furthermore, a powerful and widely used molecular marker—combined loss of the short arm of chromosome 1 and the long arm of chromosome 19—is already widely used in the management of oligodendroglial gliomas, but its role in the evaluation of astrocytic gliomas such as GBM is not yet well defined (Reifenberger and Loui…”
BackgroundSelf-citationThe Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperierre, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3414 · Cited by 728
MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS
Louis, D. N. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100043 · Cited by 648
Self-citation
Metadata
- Authors
- Reifenberger, G., & Louis, D. N.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-02
- Volume
- 62
- Issue
- 2
- Pages
- 111-126
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W2315751647
- Cited by
- 296
- References
- 87
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.